This double-blind placebo-controlled trial (n=36) investigates the effects of psilocybin on heart health (Cardiac Repolarization), the dosing includes one (not defined) extra high dose of psilocybin (supratherapeutic).
Trial DetailsThis study will be a double-blind, single-dose, randomized, placebo-controlled, 4-treatment, 4-period, 12-sequence crossover design in 36 healthy volunteers (adult male and/or female subjects). Subjects will be randomly assigned to 1 of 12 different treatment administration sequences, whereby each sequence will include 3 double-blind treatments (therapeutic dose of psilocybin, supratherapeutic dose of psilocybin, and placebo) and 1 open-label positive control treatment (moxifloxacin).
NCT Number NCT05478278
Sponsors & CollaboratorsUsona Institute
The Usona Institute was founded by Bill Linton and Malynn Utzinger. Currently, 18 people are associated with it. The institute is a non-profit that sponsors psilocybin research (and is funded by sponsors/philanthropists).